Venture - COPD

  • Study Sponsor and Protocol Number: 
    Upstream Bio, Inc. / UPB-CP-06 - VENTURE
  • Specialty:
    Pulmonology
  • Type:
    Investigational Drug 
  • Inclusion:
    Age >40 to 2 moderate or >1 severe exacerbations within the year
    Required background triple therapy (ICS, LABA, LAMA)
  • Exclusion:
    Moderate or severe COPD exacerbation within 4 weeks prior to Screening for the trial
    Treatment with oxygen of >4 L/minute (nocturnal oxygen use for sleep apnea is allowed)
    Current diagnosis of asthma